Lipocalin Muteins for GPC3 Binding Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting Glypican-3 (GPC3) in cancers such as hepatocellular carcinoma lack effective Glypican-3-binding proteins, which are essential for therapeutic and diagnostic applications.
Innovation Solution
Development of lipocalin muteins with specific binding affinity to GPC3, engineered to have substitutions at specific positions in the linear polypeptide sequence of lipocalin 2 (Lcn2), enhancing their ability to compete for binding with GPC3 and potentially used in therapeutic and diagnostic compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used for targeting GPC3, then existing therapeutic approaches can be applied, but no effective Glypican-3-binding proteins are available
Solution Approach 1:
The patent applies parameter changes by systematically mutating specific amino acid positions in the lipocalin 2 protein sequence to create variants with optimized binding affinity for GPC3. Multiple substitutions at positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 106, 125, 127, 132, and 134 were tested to achieve KD values of 10 nM or lower, directly resolving the lack of effective binding proteins.
Solution Approach 2:
The patent creates composite binding proteins by combining the lipocalin 2 scaffold with specific amino acid substitutions that confer GPC3-binding capability. The resulting muteins integrate the structural stability of lipocalin 2 with the targeted binding functionality, producing a composite therapeutic agent that simultaneously achieves reliability and adaptability.
2Reliability
If lipocalin muteins with multiple amino acid substitutions are engineered to enhance GPC3 binding, then binding affinity increases, but protein structure complexity increases
Solution Approach 1:
The patent applies local quality by introducing amino acid substitutions at specific localized positions within the lipocalin 2 structure rather than throughout the entire protein. The mutations are concentrated at positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 106, 125, 127, 132, and 134, which are strategically selected to optimize GPC3 binding while preserving the overall protein fold and minimizing structural complexity.
3Reliability
If specific amino acid substitutions are introduced to achieve high affinity binding, then binding specificity improves, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the protein engineering process into discrete, manageable steps: selecting specific amino acid positions for mutation, synthesizing individual mutein variants, testing their binding characteristics, and selecting the optimal variant. This segmented approach to creating muteins with substitutions at positions 36, 40, 41, 49, 52, 68, 70, 72, 73, 77, 79, 81, 96, 100, 103, 106, 125, 127, 132, and 134 simplifies the manufacturing process compared to de novo protein design.
Data Source
AI summary
Described are specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins include muteins of a lipocalin protein, such as lipocalin 2 (Lcn2 or NGAL). The invention also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, the invention also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.